Regeneron and Sanofi announce new positive Praluent® (alirocumab) phase 3 data
Regeneron and Sanofi announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent® (alirocumab) significantly reduced bad cholesterol. This analysis included 1,257 HeFH patients. September 01, 2015